Yunita Puspitasari, Suradi, Reviono
Departemen Pulmonologi dan Ilmu Kedokteran Respirasi, Fakultas Kedokteran Universitas Sebelas Maret, RS Dr. Moewardi Surakarta
Background: Peripheral airway inflammation and structural airway injury in COPD functionally contribute to expiratory airflow limitation. The study aims to investigate the influence of erdostein in GSH, IL-8 level, VEP₁ value and CAT score in stable chronic obstructive pulmonary disease patients.
Methods: This is a clinical single-blind randomized controlled trial study. Subjects were stable COPD outpatients of Dr. Moewardi Hospitals Surakarta. We randomized the subjects into two groups. Both groups received standard theraphy. Three hundred milligram erdostein was given twice daily in first group (n= 13) for 10 days, while the second group (n= 13) received placebo twice daily for 10 days. CAT score was carried out at the start and the completion of 10 day treatment along with measurement of severity of obstruction with forced expiratory volume in one second, GSH and IL-8 level.
Results: Erdostein significantly reduced CAT score (p=0.017). The increase of VEP₁ value between the groups was not significant (p=0.823) thus GSH (p=0.532) and IL-8 level (p=0.396). There was not significant difference between the groups after treatment in VEP₁ value (p= 0.590), CAT score (p=0.297) and IL-8 level (p=0,665).
Conclusion: Erdostein significantly reduced CAT score in stable chronic obstructive pulmonary disease patients. The increase of GSH level and VEP₁ was not significant. IL-8 level as a marker of inflammation was not decrease. (J Respir Indo. 2015; 35: 181-92)
Keywords: erdostein, stable COPD, VEP₁, CAT score, GSH level, IL-8 level.